News | December 23, 2013

Intact Vascular Announces Initiation of Tack Optimized Balloon Angioplasty Below-the-Knee Study

balloon catheters peripheral artery disease intact vascular tack-it

December 23, 2013 — Intact Vascular Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, announced the start of enrollment in the Tack Optimized Balloon Angioplasty Below the Knee (TOBA-BTK) study. This multicenter pilot study will gather data supporting the safety and performance of the Tack-It Endovascular System in 35 subjects with critical limb ischemia (CLI) due to vascular disease below the knee. A previously enrolled and ongoing clinical trial recruited patients with claudication due to vascular disease for the above the knee indication.
 
Marianne Brodmann, M.D., Medical University Hospital of Graz, Austria, and principal investigator, performed the first case. In the study, the tibial vessels targeted for treatment can range from 1.5 mm to 4.5 mm in luminal diameter using the Tack-It Endovascular System device.
 
CLI is an advanced stage of peripheral artery disease (PAD) in which patients suffer from inadequate blood flow to the lower leg and foot. If left untreated, this may lead to pain, gangrene and tissue loss (amputation). A balloon angioplasty is the most common procedure performed to attempt to restore blood flow in these blocked arteries. However, intimal dissection often occurs at the angioplasty site producing a nidus for thrombotic occlusion.
 
The Tack-It device is designed to restore tissue apposition at the site of such local dissection. It is also designed to leave minimal foreign material in the artery, apply only the minimum outward force required to reestablish intimal apposition and allow spot treatment only where needed. The system is composed of a 4 French multi-loaded catheter containing three self-expanding nitinol tacks.
 
“Stents, including balloon expandable, self-expandable or even drug-eluting stents have not been successful in treating the arteries below the knee,” said Brodmann. “Now, we are studying a smaller, less metal solution, and I believe physicians will like this for their patients. I like that I can treat only the segment in the artery where there is dissection. The device was easy to place with very precise positioning of the tacks. The Tack-It device is a nice complement to the current treatment for below the knee which is POBA.”
 
For more information: www.intactvascular.com

Related Content

News | Balloon Catheter

April 4, 2024 — The U.S. Food and Drug Administration (FDA) announced that Medos International Sàrl is recalling ...

Home April 04, 2024
Home
News | Balloon Catheter

January 18, 2024 — Summa Therapeutics, LLC announced that the first-in-man injectable angioplasty procedures for ...

Home January 18, 2024
Home
News | Balloon Catheter
Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional ...
Home February 25, 2022
Home
News | Balloon Catheter

February 15, 2022 – CERENOVUS, an emerging leader in neurovascular care and part of Johnson & Johnson Medical Devices ...

Home February 15, 2022
Home
News | Balloon Catheter

May 20, 2021 — Boston Scientific Corporation announced it has initiated the AGENT IDE trial for the Agent Drug-Coated ...

Home May 20, 2021
Home
Feature | Balloon Catheter | By Dave Fornell, Editor

The first devices developed for interventional cardiology were percutaneous transluminal coronary angioplasty (PTCA) ...

Home March 16, 2021
Home
Feature | Balloon Catheter

February 17, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Shockwave Medical's Intravascular ...

Home February 17, 2021
Home
News | Balloon Catheter

June 4, 2020 — Transit Scientific announced the U.S. Food and Drug Administration (FDA) cleared the XO Score ...

Home June 04, 2020
Home
News | Balloon Catheter

February 24, 2020 — Abbott has voluntarily recalled specific lots of two types of its coronary angioplasty catheters — ...

Home February 24, 2020
Home
News | Balloon Catheter

July 15, 2019 — Edwards LifeSciences is recalling the IntraClude Intra-Aortic Occlusion Device due to a risk of balloon ...

Home July 15, 2019
Home
Subscribe Now